Analysis method

A substantially purified polypeptide, which polypeptide:

• i) comprises the amino acid sequence as recited in any one of SEQ ID NOS:
• 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 63, 67, 69, 73, 75, 77, 85, 85a, 87, 89, 91, 93, 95, 99, 103, 113, 115, 119, 121, 129, 131, 133, 137, 139, 141, 145, 151, 153, 157, 159, 163, 169, 181, 187, 201, 205, 207, 209, 527, 529 and 531;
• ii) has an amino acid sequence encoded by a nucleic acid sequence recited in any one of SEQ ID NOS:
• 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 86a, 88, 90, 90a, 92, 92a, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 528, 530 and 532, or has an amino acid sequence encoded by a gene identified from an EST recited in any one of these SEQ ID NOS;
• iii) is a fragment of a polypeptide according to i) or ii), provided that said fragment retains a biological activity possessed by the full length polypeptide of i) or ii), or has an antigenic determinant in common with the polypeptide of i) or ii);
• or
• iv) is a functional equivalent of a polypeptide of i), ii) or (iii).

A substantially purified polypeptide, which polypeptide:

• i) comprises the amino acid sequence as recited in any one of SEQ ID NOS:
• 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 63, 67, 69, 73, 75, 77, 85, 85a, 87, 89, 91, 93, 95, 99, 103, 113, 115, 119, 121, 129, 131, 133, 137, 139, 141, 145, 151, 153, 157, 159, 163, 169, 181, 187, 201, 205, 207, 209, 527, 529 and 531 or SEQ ID NOS:
• 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 255, 257, 259, 261, 263, 265, 267, 269, 271, 273, 275, 277, 279, 281, 283, 285, 287, 289, 291, 293, 295, 297, 299, 301, 303, 305, 307, 309, 311, 313, 315, 317, 319, 321, 323, 325, 327, 329, 331, 333, 335, 337, 339, 341, 343, 345, 347, 349, 351, 353, 355, 357, 359, 361, 363, 365, 367, 369, 371, 373, 375, 377, 379, 381, 383, 385, 387, 389, 391, 393, 395, 397, 399, 401, 403, 405, 407, 409, 411, 413, 415, 417, 419, 421, 423, 425, 427, 429, 431, 433, 435, 437, 439, 441, 443, 445, 447, 449, 451, 453, 455, 457, 459, 461, 463, 465, 467, 469, 471, 473, 475, 477, 479, 481, 483, 485 and 487;
• ii) has an amino acid sequence encoded by a nucleic acid sequence recited in any one of SEQ ID NOS:
• 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 86a, 88, 90, 90a, 92, 92a, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 528, 530 and 532, or has an amino acid sequence encoded by a gene identified from an EST recited in any one of these SEQ ID NOS;
• iii) is a fragment of a polypeptide according to i) or ii), provided that said fragment retains a biological activity possessed by the full length polypeptide of i) or ii), or has an antigenic determinant in common with the polypeptide of i) or ii);
• or
• iv) is a functional equivalent of a polypeptide of i), ii) or (iii).
• for use in the diagnosis or therapy of the disease or abnormal physiological condition that is affected by hypoxia, wherein said disease or abnormal physiological condition that is treated by hypoxia is selected from the group consisting of cancer, ischaemic conditions, reperfusion injury, retinopathy, neonatal stress, preeclapmsia, atherosclerosis, inflammatory conditions, wound healing, tumourigenesis, angiogenesis, apoptosis, inflammation, erythropoiesis, hair loss, or the biological response to hypoxia conditions, including processes such as glycolysis, gluconeogenesis, glucose transportation, catecholamine synthesis, iron transport and nitric oxide synthesis.

A protein complex comprising the EGLN3 (BAB15101;

• SEQ ID NO:
• 85), the EGLN3 splice variant (SEQ ID NO:
• 85a), EGLN1 (c1orf12;
• AAG34568;
• SEQ ID NO:
• 89) or CAB81622 polypeptide, complexed with a polypeptide selected from the group consisting of Hif1alpha, Hif2alpha, Hif3alpha, a member of the PAS-domain transcription factor family, p53 and a protein binding partner that is equivalent to the beta subunit of P4H.